IL10 and myeloid sarcoma: Interestingly, in T1D patients, proinsulin peptide immunotherapy was associated with the transient appearance of Ag-specific IL-10+ CD4+ T cells (39), and in treated MS patients, a trend toward high levels of IL-10 gene expression associated with reduced Ag-specific T cell proliferation has been observed (40).